Detalhe da pesquisa
1.
Lymphotoxin-ß receptor-NIK signaling induces alternative RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer.
Mol Carcinog
; 58(3): 411-425, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30488488
2.
Anergic CD8+ T lymphocytes have impaired NF-κB activation with defects in p65 phosphorylation and acetylation.
J Immunol
; 188(3): 1213-21, 2012 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22205033
3.
Heterogeneous characterization of neutrophilic cells in head and neck cancers.
Head Neck
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622975
4.
Quantification and Functional Studies of Neutrophilic Cells Identifies Distinct Papilloma Phenotypes.
Laryngoscope
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38436434
5.
Oncogenic Ras and ΔNp63α cooperate to recruit immunosuppressive polymorphonuclear myeloid-derived suppressor cells in a mouse model of squamous cancer pathogenesis.
Front Immunol
; 14: 1200970, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37638000
6.
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
J Immunother Cancer
; 9(8)2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34462327
7.
Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes.
Commun Biol
; 4(1): 1416, 2021 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34931021
8.
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
J Immunother Cancer
; 9(3)2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33741731
9.
Myeloid-Derived Suppressive Cell Expansion Promotes Melanoma Growth and Autoimmunity by Inhibiting CD40/IL27 Regulation in Macrophages.
Cancer Res
; 81(23): 5977-5990, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34642183
10.
ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer.
Oncoimmunology
; 9(1): 1710398, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32002309
11.
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Clin Cancer Res
; 26(6): 1420-1431, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31848188
12.
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Elife
; 92020 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32633234
13.
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
Clin Cancer Res
; 26(3): 679-689, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31645352
14.
Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors.
Cancer Immunol Res
; 7(3): 401-413, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30683733
15.
Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
Cancer Immunol Res
; 7(2): 282-291, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30514791
16.
Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition.
Oncoimmunology
; 8(11): e1638207, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31646086
17.
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
J Immunother Cancer
; 7(1): 119, 2019 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31053174
18.
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
JCI Insight
; 4(7)2019 04 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30944253
19.
Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer.
Clin Cancer Res
; 25(9): 2860-2873, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30723145
20.
WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.
Oncoimmunology
; 7(10): e1488359, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30288354